Selection Patent for Apixaban Upheld by Federal Court of Appeal

2022 FCA 142: The Court also commented on the relevant date for determining if an invention has been sufficiently described in the patent application.

READ MORE →

Stay informed. Subscribe to PCK IP’s insights for our latest commentary and updates.